Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?

Arab Journal of Gastroenterology

Volumn 13, Issue 3, 2012, Pages 111-115

  Mohamed, Nadia A ^a   Swify, Eman M ^a   Amin, Nabila F ^a   Soliman, Mona M ^a   Tag Eldin, Lubna M ^a   Elsherbiny, Nahla M ^a  

^a Assiut University Faculty of Medicine   (Egypt)

Author keywords

Chronic viral hepatitis C; Hepatocellular carcinoma; Methylated RASSF1A

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA METHYLATION; DNA SEQUENCE; EARLY DIAGNOSIS; FEMALE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84868301113     PISSN: 16871979     EISSN: 20902387     Source Type: Journal    
DOI: 10.1016/j.ajg.2012.06.009     Document Type: Article

References (38)

1. McGlynn K.A., London W.T. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005, 19(1):3-23.
2. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006, 25(27):3834-3847.
3. Yahia M. Global health: a uniquely Egyptian epidemic. Nature 2011, 474(7350 Suppl.). S12-3.
4. Nagai H., Sumino Y. Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent Pat Anti-Cancer Drug Discov 2008, 3(3):220-226.
5. Kung J.W.C., MacDougall M., Madhavan K.K., et al. Predicting survival in patients with hepatocellular carcinoma: a UK perspective. Eur J Surg Oncol 2007, 33(2):188-194.
6. Rivenbark A.G., Coleman W.B. The use of epigenetic biomarkers for preclinical detection of hepatocellular carcinoma: potential for noninvasive screening of high-risk populations. Clin Cancer Res 2007, 13(8):2309-2312.
7. Sherman M. Diagnosis of small hepatocellular carcinoma. Hepatology 2005, 42(1):14-16.
8. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002, 2(3):210-219.
9. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31(4):339-346.
10. Zhu J. DNA methylation and hepatocellular carcinoma. J Hepatobiliarypancreat Surg 2006, 13(4):265-273.
11. Asselah T., Bièche I., Sabbagh A., et al. Gene expression and hepatitis C virus infection. Gut 2009, 58(6):846-858.
12. Formeister E.J., Tsuchiya M., Fujii H., et al. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res 2010, 692(1-2):26-33.
13. Dammann R., Yang G., Pfeifer G.P. Hypermethylation of the CpG island of Ras association domain Family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001, 61(7):3105-3109.
14. Peters I., Vaske B., Albrecht K., et al. Adiposity and age are statistically related to enhanced RASSF1A tumor suppressor gene promoter methylation in normal autopsy kidney tissue. Cancer Epidemiol Biomarkers Prev 2007, 16(12):2526-2532.
15. Pallarés J., Velasco A., Eritja N., et al. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol 2008, 21(6):691-699.
16. Wang T., Liu H., Chen Y., et al. Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. J Exp Clin Cancer Res 2009, 28(1). Art. No. 160.
17. Zhang Y.J., Wu H.C., Shen J., et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 2007, 13(8):2378-2384.
18. Hu L., Chen G., Yu H., et al. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 2010, 4(1):423-432.
19. Di Gioia S., Bianchi P., Destro A., et al. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer 2006, 6:12. Art. No. 89.
20. Saelee P., Wongkham S., Chariyalertsak S., et al. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma. Asian Pac J Cancer Prev 2010, 11(6):1677-1681.
21. Lambert M.P., Paliwal A., Vaissière T., et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 2011, 54(4):705-715.
22. Feng Q., Stern J.E., Hawes S.E., et al. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol 2010, 88(2):287-292.
23. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
24. Chan K.C.A., Ding C., Gerovassili A., et al. Hypermethylated RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006, 52(12):2211-2218.
25. Wang Y.C., Yu Z.H., Liu C., et al. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol 2008, 14(19):3074-3080.
26. Nishida N., Nagasaka T., Nishimura T., et al. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis and hepatocellular carcinoma. Hepatology 2008, 47(3):908-918.
27. Chan K.C.A., Lai P.B.S., Mok T.S.K., et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 2008, 54(9):1528-1536.
28. Iyer P., Zekri A.R., Hung C.W., et al. Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Exp Mol Pathol 2010, 88(1):107-111.
29. Chang H., Yi B., Li L., et al. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients. Exp Mol Pathol 2008, 85(2):96-100.
30. Calvisi D.F., Ladu S., Gorden A., et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007, 117(9):2713-2722.
31. Azab N.I., Abd El Kariem H.M., Mowafi T., et al. Blood Ras-association domain family 1 A gene methylation status in some liver diseases. Life Sci J 2011, 8(2):531-539.
32. Attia M.A. Prevalence of hepatitis B and C in Egypt and Africa. Antivir Ther 1998, 3(Suppl. 3):1-9.
33. El Zayadi A. Hepatitis B virus infection: the Egyptian situation. Arab J Gastroenterol 2007, 8:94-98.
34. El Zanaty F, Way A. Egypt demographic and health survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates and Macro International; 2009.
35. Guo N., Chen R., Li Z., et al. Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells. Acta Biochim Biophys Sin 2011, 43(5):354-361.
36. Yeo W., Wong N., Wong W.L., et al. High frequency of promoter hypermethylation of RASSF1A in tumor and serum of patients with hepatocellular carcinoma. Liver Int 2005, 25:266-272.
37. Moribe T., Iizuka N., Miura T., et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer 2009, 125(2):388-397.
38. Su H., Zhao J., Xiong Y., et al. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from southeast China. Mutat Res 2008, 641(1-2):27-35.